168 related articles for article (PubMed ID: 25416449)
1. Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro.
Yamaguchi M; Zhu S; Weitzmann MN; Snyder JP; Shoji M
Mol Cell Biochem; 2015 Mar; 401(1-2):1-10. PubMed ID: 25416449
[TBL] [Abstract][Full Text] [Related]
2. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
[TBL] [Abstract][Full Text] [Related]
3. Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition.
Yamaguchi M; Moore TW; Sun A; Snyder JP; Shoji M
Integr Biol (Camb); 2012 Aug; 4(8):905-13. PubMed ID: 22751853
[TBL] [Abstract][Full Text] [Related]
4. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
Yamaguchi M; Vikulina T; Weitzmann MN
Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
[TBL] [Abstract][Full Text] [Related]
5. The flavonoid p-hydroxycinnamic acid mediates anticancer effects on MDA-MB-231 human breast cancer cells in vitro: Implications for suppression of bone metastases.
Yamaguchi M; Murata T; Shoji M; Weitzmann MN
Int J Oncol; 2015 Oct; 47(4):1563-71. PubMed ID: 26238204
[TBL] [Abstract][Full Text] [Related]
6. Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; Shoji M; Murata T
Int J Oncol; 2016 Aug; 49(2):812-22. PubMed ID: 27221776
[TBL] [Abstract][Full Text] [Related]
7. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
8. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
10. Three-Dimensional in Vitro Model to Study Osteobiology and Osteopathology.
Krishnan V; Vogler EA; Mastro AM
J Cell Biochem; 2015 Dec; 116(12):2715-23. PubMed ID: 26039562
[TBL] [Abstract][Full Text] [Related]
11. Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.
Browne AJ; Kubasch ML; Göbel A; Hadji P; Chen D; Rauner M; Stölzel F; Hofbauer LC; Rachner TD
Breast Cancer Res; 2017 Aug; 19(1):92. PubMed ID: 28793923
[TBL] [Abstract][Full Text] [Related]
12. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
13. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone.
Tamura D; Hiraga T; Myoui A; Yoshikawa H; Yoneda T
Int J Oncol; 2008 Jul; 33(1):17-24. PubMed ID: 18575746
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
15. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
16. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation.
Mercer RR; Miyasaka C; Mastro AM
Clin Exp Metastasis; 2004; 21(5):427-35. PubMed ID: 15672867
[TBL] [Abstract][Full Text] [Related]
17. Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts.
Zhu S; Moore TW; Morii N; Howard RB; Culver D; Arrendale RF; Reddy P; Evers TJ; Zhang H; Sica G; Chen ZG; Sun A; Fu H; Khuri FR; Shin DM; Snyder JP; Shoji M
Curr Cancer Drug Targets; 2014; 14(4):380-93. PubMed ID: 24628271
[TBL] [Abstract][Full Text] [Related]
18. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
[TBL] [Abstract][Full Text] [Related]
20. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
